Gene fusions involving the anaplastic lymphoma kinase gene (ALK) often leads to oncogenic activation of the ALK kinase resulting in tumor development in lung and other solid tumors. Accurate identification of the fusion gene in patients with lung cancer has profoundly impacted patients’ clinical performance and long-term survival. READ ARTICLE
Clinical Lung Cancer DOI:10.1016/j.cllc.2018.11.002
Authors: Hongzheng Ren, Xiaonan Hou, Patrick W. Eiken, Jin Zhang, Karlyn E. Pierson, Asha A. Nair, Jaime I. Davila, Helena Kovarikova, Jin Sung Jang, Sarah H. Johnson, Julian R. Molina, Randolph S. Marks, Ping Yang, Joanne E. Yi, Aaron S. Mansfield, Jin Jen